Atea Pharmaceuticals, Inc. (AVIR)
Largest Insider Buys in Sector
AVIR Stock Price History Chart
AVIR Stock Performance
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Insider Activity of Atea Pharmaceuticals, Inc.
Over the last 12 months, insiders at Atea Pharmaceuticals, Inc. have bought $0 and sold $1.81M worth of Atea Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Atea Pharmaceuticals, Inc. have bought $6.55M and sold $1.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $102,796 was made by Murphy Polly A. (director) on 2021‑12‑20.
List of Insider Buy and Sell Transactions, Atea Pharmaceuticals, Inc.
| 2024-12-10 | Sale | director | 359,606 0.42% | $2.85 | $1.02M | +11.05% | ||
| 2024-09-19 | Sale | President, CEO, and Chairman | 1,841 0.0026% | $4.00 | $7,368 | -12.04% | ||
| 2024-09-18 | Sale | President, CEO, and Chairman | 22,187 0.031% | $4.03 | $89,469 | -15.79% | ||
| 2024-09-17 | Sale | President, CEO, and Chairman | 33,941 0.0475% | $4.05 | $137,319 | -16.42% | ||
| 2024-06-20 | Sale | director | 17,544 0.0212% | $3.49 | $61,144 | +0.29% | ||
| 2024-06-05 | Sale | President, CEO, and Chairman | 1,006 0.0014% | $4.00 | $4,024 | -13.13% | ||
| 2024-02-01 | Sale | See Remarks | 15,843 0.0211% | $3.84 | $60,915 | -13.03% | ||
| 2024-02-01 | Sale | President, CEO, and Chairman | 56,910 0.0758% | $3.85 | $218,819 | -13.03% | ||
| 2024-02-01 | Sale | Chief Development Officer | 14,029 0.0187% | $3.84 | $53,913 | -13.03% | ||
| 2024-02-01 | Sale | Chief Medical Officer | 15,870 0.0211% | $3.84 | $60,963 | -13.03% | ||
| 2024-02-01 | Sale | Chief Commercial Officer | 11,819 0.0157% | $3.84 | $45,420 | -13.03% | ||
| 2024-02-01 | Sale | EVP, Chief Accounting Officer | 12,477 0.0166% | $3.84 | $47,904 | -13.03% | ||
| 2022-11-14 | Sale | director | 16,166 0.0289% | $5.16 | $83,352 | -31.57% | ||
| 2022-11-11 | Sale | director | 25,500 0.0455% | $5.15 | $131,333 | -32.40% | ||
| 2021-12-20 | director | 12,000 0.0356% | $8.57 | $102,796 | -21.40% | |||
| 2020-11-03 | director | 250,000 2.0771% | $24.00 | $6M | +10.66% | |||
| 2020-11-03 | 10 percent owner | 250,000 2.0771% | $24.00 | $6M | +10.66% | |||
| 2020-11-03 | director | 41,666 0.3462% | $24.00 | $999,984 | +10.66% |
Insider Historical Profitability
| Sommadossi Jean-Pierre | President, CEO, and Chairman | 5866025 6.9451% | $3.35 | 0 | 5 | |
| Corcoran Andrea | See Remarks | 670208 0.7935% | $3.35 | 0 | 1 | |
| BERGER FRANKLIN M | director | 451897 0.535% | $3.35 | 1 | 3 | |
| Polsky Bruce | director | 65606 0.0777% | $3.35 | 0 | 1 | |
| Hammond Janet MJ | Chief Development Officer | 35362 0.0419% | $3.35 | 0 | 1 | |
| Horga Maria Arantxa | Chief Medical Officer | 25664 0.0304% | $3.35 | 0 | 1 | |
| Vavricka John | Chief Commercial Officer | 21515 0.0255% | $3.35 | 0 | 1 | |
| Foster Wayne | EVP, Chief Accounting Officer | 20857 0.0247% | $3.35 | 0 | 1 | |
| Hack Andrew A. F. | director | 5615659 6.6487% | $3.35 | 1 | 0 | |
| Rock Springs Capital Management LP | 10 percent owner | 1654724 1.9591% | $3.35 | 1 | 0 | |
| Murphy Polly A. | director | 23295 0.0276% | $3.35 | 1 | 0 | <0.0001% |